BMEA Biomea Fusion, Inc.
Price Chart
Executive Summary
Biomea Fusion updated its corporate presentation, highlighting positive clinical data from its Phase II trial (COVALENT-111) for icovamenib in type 2 diabetes. The data shows durable HbA1c reduction and increased C-peptide levels lasting 52 weeks after a 12-week treatment course, suggesting potential disease modification. The company is advancing two Phase II trials with data expected in Q4 2026 and is funded into Q1 2027.
Actionable Insight
Monitor for upcoming Phase II data readouts in Q4 2026, which could be pivotal for the drug's development. The durable effects after short-term treatment suggest a potentially transformative mechanism, making this a high-risk, high-reward catalyst for the stock.
Key Facts
- Icovamenib demonstrated durable HbA1c reduction of 1.2% at 52 weeks after a 12-week treatment course in insulin-deficient T2D patients (p=0.01).
- Icovamenib increased insulin secretion (C-peptide) by 24% at 52 weeks in severe insulin-deficient patients.
- Two Phase II trials (COVALENT-211 and COVALENT-212) are ongoing with 26-week primary endpoint data anticipated in Q4 2026.
- The drug showed a favorable 52-week safety profile with no treatment-related serious adverse events.
- Biomea is funded through key clinical readouts for icovamenib and BMF-650 into Q1 2027.
Financial Impact
No direct financial figures provided in the filing.
Risk Factors
- Clinical trial results may not be replicated in larger studies.
- Regulatory approval is not guaranteed despite positive early data.
- Competition from existing and emerging diabetes treatments.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-068375 |
| Document: d95198d8k.htm | 0001193125-26-068375 |
| Document: 0001193125-26-068375-index-headers.html | 0001193125-26-068375 |
| Document: 0001193125-26-068375-index.html | 0001193125-26-068375 |
| Document: 0001193125-26-068375.txt | 0001193125-26-068375 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Institutional Cluster
| $1.20 awaiting T+5 | awaiting T+5 | — | $1.17 (−2.50%) |
|
Jun 5, 2026
9d ago
|
Press Release
| $1.29 awaiting T+5 | awaiting T+5 | — | $1.17 (−9.30%) |
|
May 11, 2026
4w ago
|
8-K
| $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $1.17 (−25.95%) |
|
May 11, 2026
4w ago
|
Press Release
| $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $1.17 (−25.95%) |
|
Apr 28, 2026
6w ago
|
8-K
| $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $1.17 (−23.53%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $1.17 (−23.53%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $1.53 $1.76 | ▲ +15.03% | ▲ +11.09% | $1.17 (−23.53%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $1.22 $1.49 | ▲ +22.13% | ▲ +22.37% | $1.17 (−4.10%) |
|
Feb 25, 2026
15w ago
|
8-K
| $1.41 $1.39 | ▼ −1.42% | ▼ −0.32% | $1.17 (−17.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access